［1］Sinha A，Ignatchenko V，Ignatchenko A，et al.In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome［J］.Biochem Biophys Res Commun，2014，445(4)：694-701.
[2]Ferrero A，Ditto A，Giorda G，et al.Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer：A multicenter study［J］.Eur J Surq Oncol，2014，40(7)：891-898.
[3]Jr RJM，Alvarez RD，Armstrong DK，et al.Ovarian cancer，version 2.2013：Featured updates to the NCCN guidelines［J］.Journal of the National Comprehensive Cancer Network，2013，11(10)：1199-1209.
[4]TCGA.Cancer genome atlas research network：Integrated genomic analyses of ovarian carcinoma［J］.Nature，2011（474）：609-615.
[5]Galaal K，Naik R，Bristow RE，et al.Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer［J］.Cochrane Database Syst Rev，2010，16(6)：CD007822.
[6]Parmar MK，Ledermann JA，Colombo N，et al.Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer：The ICON4/AGO-OVAR-2.2 trial［J］.Lancet，2003，361(9375)：2099-2106.
[7]Pfisterer J，Plante M，Vergote I，et al.Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer：An intergroup trial of the AGO-OVAR，the NCIC CTG，and the EORTC GCG［J］.J Clin Oncol，2006，24(29)：4699-4707.
[8]Wagner U，Marth C，Largillier R，et al.Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients［J］.Br J Cancer，2012，107(4)：588-591.
[9]Bruchim I，Weeg N，Alpert Y，et al.High efficacy and low toxicity of the modified docetaxel and carboplatin protocol in patients with recurrent ovarian cancer-a phase 2 cohort study［J］.Int J Gynecol Cancer，2016，26(4)：640-647.
[10]Zhang Y，Ba Y，Liu C，et al.PGC-1alpha induces apoptosis in human epithelial ovarian cancer cells through a PPARgamma-dependent pathway［J］.Cell Res，2007，17(4)：363-373.
[11]Zhang MC，Li P，Ha MW，et al.Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer［J］.Journal of Shandong University(Health Science)，2014，52(11)：55-59.
[12]Monk BJ，Coleman RL.Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer：From platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds［J］.Int J Gynecol Cancer，2009，19(11)：S63-637.
[13]NCCN Clinical Practice Guideline in Oncology(NCCN Guidelines).Ovarian cancer including fallopian tube cancer andprimary peritoneal cancer version1［EB/OL］.［2017-04-12］https：//www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian.
[14]Naumann RW，Coleman RL.Management strategies for recurrent platinum-resistant ovarian cancer［J］.Drugs，2011，71(11)：1397-1412.
[15]Loizzi V，Vecchio VD，Gargano G，et al.Biological pathways involved in tumor angiogenesis and bevacizumab based anti-angiogenic therapy with special references to ovarian cancer［J］.Int J Mol Sci，2017，18(9)：1967.
[16]Aghajanian C，Blank SV，Goff BA，et al.OCEANS：A randomized，double-blind，placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian，primary peritoneal，or fallopian tube cancer［J］.J Clin Oncol，2012，30(17)：2039-2045.
[17]Coleman RL，Brady MF，Herzog TJ，et al.Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent，platinum-sensitive ovarian cancer(NRG Oncology/Gynecologic Oncology Group study GOG-0213)：A multicentre，open-label，randomised，phase 3 trial［J］.Lancet Oncol，2017，18(6)：779-791.
[18]MA LF，ZHOU Q，LI R.Short-term efficacy and safety of bevacizumab combined with chemotherapy in platinum-sensitive recurrent ovarian cancer［J］.Chongqing Medicine，2017，46(11)：1532-1535.［马丽芳，周琦，李蓉.贝伐单抗联合化疗对铂敏感型复发性卵巢癌的近期疗效及安全性研究［J］.重庆医学，2017，46(11)：1532-1535.］
[19]Fuh KC，Secord AA，Bevis KS，et al.Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients［J］.Gynecol Oncol，2015，139(3)：413-418.
[20]Pujade-Lauraine E，Hilpert F，Weber B，et al.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer：The AURELIA open-label randomized phase III trial［J］.J Clin Oncol，2014，32(13)：1302-1308.
[21]Sorio R，Roemer-becuwe C，Hilpert F，et al.Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer：Subgroup analysis of the randomised phase III AURELIA trial［J］.Gynecol Oncol，2017，144(1)：65-71.
[22]Trillsch F，Mahner S，Hilpert F，et al.Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial［J］.Ann Oncol，2016，27(9)：1733-1739.
[23]Huang H，Zheng Y，Zhu J，et al.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients［J］.Plos One，2014，9(3)：e89960.
[24]Ledermann JA，Harter P，Gourley C，et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy：An updated analysis from a randomised，placebo-controlled，double-blind，phase 2 trial［J］.Lancet Oncol，2016，17(11)：1579-1589.
[25]Pujade-Lauraine E，Ledermann JA，Selle F，et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive，relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21)：A double-blind，randomised，placebo-controlled，phase 3 trial［J］.Lancet Oncol，2017，18(9)：1274-1284.
[26]Ledermann J，Harter P，Gourley C，et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer：A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial［J］.Lancet Oncol，2014，15(8)：852-861.
[27]Oza AM，Cibula D，Benzaquen AO，et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer：A randomised phase 2 trial［J］.Lancet Oncol，2015，16(1)：87-97.
[28]LIANG JH，LUO RL.Therapeutic effects and safety of olaparib on treatment of recurrent serosity ovarian cancer：A meta-analysis［J］.Journal of Hubei Medical University，2015，34(06)：538-542，547.［梁江红，罗蕊丽.奥拉帕尼维持疗法对复发性浆液性卵巢癌的疗效及安全性Meta分析［J］.湖北医药学院学报，2015，34(06)：538-542，547.］
[29]WANG LL，LI X，HOU DK，et al.Clinical observations of six advanced refractory ovarian cancer cases treated with apatinib［J］.Chin J Clin Oncol，2018，45(07)：362-365.［王丽丽，李鑫，侯定坤，等.阿帕替尼治疗6例晚期难治性卵巢癌的临床观察［J］.中国肿瘤临床，2018，45(07)：362-365.］
[30]Choi N，Chang JH，Kim S，et al.Radiation for persistent or recurrent epithelial ovarian cancer：A need for reassessment［J］.Radiat Oncol J，2017，35(2)：144-152.
[31]Lee M，Kim SW，Lee SH，et al.Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer［J］.Int J Gynecol Cancer，2011，21(6)：1032-1039.
[32]Machida S，Takei Y，Yoshida C，et al.Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer［J］.Oncology，2014，86(4)：232-238.
[33]Albuquerque K，Patel M，Liotta M，et al.Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer［J］.Int J Gynecol Cancer，2016，26(4)：655-660.
[34]Wang X，Goldstein D，Crowe PJ，et al.Impact of STAT3 inhibition on survival of osteosarcoma cell lines［J］.Anticancer Res，2014，34(11)：6537-6545.
[35]DANG YZ，HUANG SG.Research progress of biological intensity modulated radiation therapy for advanced ovarian cancer［J］.Medical Journal of West China，2015，27(9)：1281-1285.［党亚正，黄世高.晚期卵巢癌三维适形和调强放疗研究现状与展望［J］.西部医学，2015，27(9)：1281-1285.］
[36]Biete A，Valduvieco I，Rovirosa A，et al.Whole abdominal radiotherapy in ovarian cancer［J］.Rep Pract Oncol Radiother，2010，15(2)：27-30.
[37]Rochet N，Sterzing F，Jensen AD，et al.Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer：Phase I study［J］.Int J Radiat Oncol Biol Phys，2010，76(5)：1382-1389.
[38]Rochet N，Kieser M，Sterzing F，et al.Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy(IMRT)in patients with advanced ovarian cancer stage FIGO III-The OVAR-IMRT-02 Study［J］.BMC Cancer，2011（11）：41.
[39]Arians N，Kieser M，Benner L，et al.Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer(International Federation of Gynecology and Obstetrics stage III)：First results of a prospective phase 2 study［J］.Int J Radiat Oncol Biol Phys，2017，99(4)：912-920.
[40]SHEN J，ZHANG FQ.The role of radiotherapy for patients with recurrent ovarian cancer［J］.Journal of Practical Obstetrics and Gynecology，2017，33(11)：812-815.［沈晶，张福泉.放疗在复发性卵巢癌治疗中的作用［J］.实用妇产科杂志，2017，33(11)：812-815.］
[41]LIU XY，ZHENG J.Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer［J］.Modern Journal of Integrated Traditional Chinese and Western Medicine，2016，25(32)：3599-3601.［刘旭阳，郑静.适形放疗联合托泊替康化疗治疗铂类耐药的复发卵巢癌疗效观察［J］.现代中西医结合杂志，2016，25(32)：3599-3601.］
[42]Wei P，Zhang ZH，Li L，et al.Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer［J］.Genet Mol Res，2015，14(2)：3833-3842.
[43]ZHOU LJ.Clinical observation of chemotherapy combined with three-dimensional radiotherapy for recurrent ovarian cancer［J］.Guide of China Medicine，2014，12(14)：90-91.［周隆军.化疗联合三维适行放疗治疗复发卵巢癌的临床观察［J］.中国医药指南，2014，12(14)：90-91.］
[44]Du XL，Jiang T，Sheng XG，et al.PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer［J］.Eur J Radiol，2012，81(11)：3551-3556.
[45]Suh DH，Kim HS，Chang SJ，et al.Surgical management of recurrent ovarian cancer［J］.Gynecol Oncol，2016，142(2)：357-367.
[46]Zang RY，Harter P，Chi DS，et al.Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort［J］.Br J Cancer，2011，105(7)：890-896.
[47]Fan XM，Zhang J，Niu SH，et al，Secondary cytoreductive surgery in recurrent ovarian cancer：A prognostic analysis with 103 cases［J］.Int J Surg,2017(38)：61-66.
[48]WANG FP，ZHANG XY，JIANG XC，et al.Clinical effect of secondary cytoreductive surgery combined with chemotherapy on recurrent ovarian cancer and its influence on patients life quality［J］.Journal of Guangxi Medical University，2017，34(8)：1157-1160.［王飞鹏，张晓英，姜晓春，等.二次肿瘤细胞减灭术联合化疗治疗复发性卵巢癌的临床效果及对患者生活质量的影响［J］.广西医科大学学报，2017，34(8)：1157-1160.］
[49]CHENG JY，WU XH.Surgical strategy for recurrent ovarian cancer［J］.Journal of Practical Obstetrics and Gynecology，2017，33(11)：803-806.［程婧仪，吴小华.复发性卵巢癌的手术策略［J］.实用妇产科杂志，2017，33(11)：803-806.］